140 related articles for article (PubMed ID: 31654541)
1. Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.
Del Mar Álvarez-Torres M; Juan-Albarracín J; Fuster-Garcia E; Bellvís-Bataller F; Lorente D; Reynés G; Font de Mora J; Aparici-Robles F; Botella C; Muñoz-Langa J; Faubel R; Asensio-Cuesta S; García-Ferrando GA; Chelebian E; Auger C; Pineda J; Rovira A; Oleaga L; Mollà-Olmos E; Revert AJ; Tshibanda L; Crisi G; Emblem KE; Martin D; Due-Tønnessen P; Meling TR; Filice S; Sáez C; García-Gómez JM
J Magn Reson Imaging; 2020 May; 51(5):1478-1486. PubMed ID: 31654541
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
[TBL] [Abstract][Full Text] [Related]
3. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI.
Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA
J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.
Leu K; Boxerman JL; Lai A; Nghiemphu PL; Pope WB; Cloughesy TF; Ellingson BM
J Magn Reson Imaging; 2016 Nov; 44(5):1229-1237. PubMed ID: 26971534
[TBL] [Abstract][Full Text] [Related]
6. Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtype.
Chelebian E; Fuster-Garcia E; Álvarez-Torres MDM; Juan-Albarracín J; García-Gómez JM
PLoS One; 2020; 15(10):e0232500. PubMed ID: 33052913
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
[TBL] [Abstract][Full Text] [Related]
8. Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort.
Kim M; Park JE; Yoon SK; Kim N; Kim YH; Kim JH; Kim HS
Eur Radiol; 2023 Jun; 33(6):4475-4485. PubMed ID: 36242633
[TBL] [Abstract][Full Text] [Related]
9. Preoperative vascular heterogeneity based on dynamic susceptibility contrast MRI in predicting spatial pattern of locally recurrent high-grade gliomas.
Wang H; Zeng L; Wu H; Tian J; Xie H; Zhang L; Ran Q; Zhong P; Chen L; Yi L; Wang S
Eur Radiol; 2024 Mar; 34(3):1982-1993. PubMed ID: 37658897
[TBL] [Abstract][Full Text] [Related]
10. Multiparameter MRI Predictors of Long-Term Survival in Glioblastoma Multiforme.
Stringfield O; Arrington JA; Johnston SK; Rognin NG; Peeri NC; Balagurunathan Y; Jackson PR; Clark-Swanson KR; Swanson KR; Egan KM; Gatenby RA; Raghunand N
Tomography; 2019 Mar; 5(1):135-144. PubMed ID: 30854451
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
12. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
[TBL] [Abstract][Full Text] [Related]
13. Low-dose T1W DCE-MRI for early time points perfusion measurement in patients with intracranial tumors: A pilot study applying the microsphere model to measure absolute cerebral blood flow.
Li KL; Lewis D; Jackson A; Zhao S; Zhu X
J Magn Reson Imaging; 2018 Aug; 48(2):543-557. PubMed ID: 29473980
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma.
Steidl E; Filipski K; Hattingen E; Steinbach JP; Maurer GD
PLoS One; 2023; 18(2):e0274400. PubMed ID: 36724187
[TBL] [Abstract][Full Text] [Related]
15. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
Chaddad A; Sabri S; Niazi T; Abdulkarim B
Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
[TBL] [Abstract][Full Text] [Related]
16. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
[TBL] [Abstract][Full Text] [Related]
17. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
[TBL] [Abstract][Full Text] [Related]
18. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
[TBL] [Abstract][Full Text] [Related]
19. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
[TBL] [Abstract][Full Text] [Related]
20. Quantitative histopathologic assessment of perfusion MRI as a marker of glioblastoma cell infiltration in and beyond the peritumoral edema region.
Vallatos A; Al-Mubarak HFI; Birch JL; Galllagher L; Mullin JM; Gilmour L; Holmes WM; Chalmers AJ
J Magn Reson Imaging; 2019 Aug; 50(2):529-540. PubMed ID: 30569620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
